Date | Title | Description | |
---|---|---|---|
31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
26 Jun 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
24 Jun 2024 | On business and financial situation | ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth | Download |
08 May 2024 | On P&L | The Company releases the press release related to the first three months of 2024 financial results | Download |
Pages
Date | Title | Description | |
---|---|---|---|
02 Apr 2024 | On business and financial situation | ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia | Download |
29 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 22 March and 27 March 2024 | Download |
22 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 March and 21 March 2024 | Download |
15 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 8 March and 14 March 2024 | Download |
12 Mar 2024 | On business and financial situation | ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies | Download |